Scarica l'app Stockscreener
1.53
1.29%
-0.02
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 0.7% Higher - Defense World
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 0.7% Higher - MarketBeat
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease - StockTitan
Citius Pharmaceuticals defers FDA milestone payment - Investing.com
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
TD Cowen holds Buy on Milestone Pharmaceuticals stock, expects peak sales of $441M - Investing.com
TD Cowen holds Buy on Milestone Pharmaceuticals stock, expects peak sales of $441M - Investing.com Canada
Hemogenyx Pharmaceuticals passes crucial milestone ahead of phase I trial - Proactive Investors UK
Etripamil nasal spray shows promise in China trial By Investing.com - Investing.com Australia
Etripamil nasal spray shows promise in China trial By Investing.com - Investing.com Canada
Etripamil nasal spray shows promise in China trial - Investing.com
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China - GlobeNewswire Inc.
Milestone Pharmaceuticals welcomes new board member Joseph Papa - Investing.com
Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration - Business Wire
Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80 - Yahoo Finance
Brokers Offer Predictions for Milestone Pharmaceuticals Inc.'s FY2024 Earnings (NASDAQ:MIST) - MarketBeat
Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024 - StockTitan
HC Wainwright Analysts Lower Earnings Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals (NASDAQ:MIST) Given “Buy” Rating at HC Wainwright - Defense World
Rodman & Renshaw Initiates Coverage of Milestone Pharmaceuticals (MIST) with Buy Recommendation - MSN
HC Wainwright Reaffirms "Buy" Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from Analysts at Rodman & Renshaw - MarketBeat
Milestone stock wins Buy at Rodman Renshaw (NASDAQ:MIST) - Seeking Alpha
Milestone Pharmaceuticals (NASDAQ:MIST) Coverage Initiated at Rodman & Renshaw - Defense World
Thinking about buying stock in Cellebrite DI, Milestone Pharmace - GuruFocus.com
Thinking about buying stock in Mogo Inc, Rigetti Computing, Apte - GuruFocus.com
Milestone Pharmaceuticals: Q2 Earnings Snapshot - CTPost
MISTMilestone Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Milestone Pharmaceuticals: Q2 Earnings Snapshot - CT Insider
Milestone Pharmaceuticals: Q2 Earnings Snapshot - San Antonio Express-News
Milestone Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - wallstreet:online
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - StockTitan
Agios Pharmaceuticals' Shares Rise Ahead of $1.1B in Milestone Payments - MarketWatch
Agios to receive $1.1B in milestone payments for vorasidenib approval (NASDAQ:AGIO) - Seeking Alpha
Contrasting AstraZeneca (NASDAQ:AZN) & Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World
SIPP Industries Announces Milestone Achievements in Partnership with Calypso Pharmaceuticals - StockTitan
Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference - StockTitan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stake Boosted by BNP Paribas Financial Markets - Defense World
Mirum Pharmaceuticals hits all-time high at $40.76, marking a significant milestone - Investing.com India
Mirum Pharmaceuticals hits all-time high at $40.76, marking a significant milestone - Investing.com Nigeria
Mirum Pharmaceuticals hits all-time high at $40.76, marking a significant milestone - Investing.com
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 2.7% Higher - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 2.7% Higher - Defense World
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties - GlobeNewswire
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million - Yahoo Finance
Milestone Pharmaceuticals adds two new board members - Investing.com India
Milestone Pharmaceuticals adds two new board members By Investing.com - Investing.com Canada
Milestone Pharmaceuticals adds two new board members - Investing.com
Milestone Pharmaceuticals Refreshes Board of Directors - StockTitan
FuelCell Energy Marks a Significant Milestone in Korean Market Expansion - Yahoo Finance
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 - StockTitan
Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration - Yahoo Finance
iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial - Yahoo Finance
iTeos Announces First Patient Dosed in GALAXIES Lung-301 - GlobeNewswire
ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com
Milestone Pharma stock holds buy rating at H.C. Wainwright on expansion potential By Investing.com - Investing.com UK
Milestone Pharmaceuticals (NASDAQ:MIST) Receives “Buy” Rating from HC Wainwright - Defense World
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone - Yahoo Finance
Top Ranked Momentum Stocks to Buy for May 19th - Yahoo Lifestyle UK
Nothing is Better Than Milestone Pharmaceuticals Inc (MIST) stock at the moment – Sete News - SETE News
Revir Therapeutics and Asieris announce milestone under oncology collaboration - BioWorld Online
Biopharma Layoff Tracker 2024: Barinthus, Agilent, BMS and More Cut Staff - BioSpace
1.07%
2.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):